A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Pfizer
Novartis
AstraZeneca
AstraZeneca
Eli Lilly and Company
Stemline Therapeutics, Inc.
Eli Lilly and Company
Olema Pharmaceuticals, Inc.
Genentech, Inc.
Shandong Suncadia Medicine Co., Ltd.
Tolmar Inc.
Tolmar Inc.
Jiangsu Simcere Pharmaceutical Co., Ltd.
Stemline Therapeutics, Inc.
Eli Lilly and Company
AstraZeneca
Veru Inc.
Veru Inc.
Chipscreen Biosciences, Ltd.
Taizhou EOC Pharma Co., Ltd.
Novartis
Novartis
Novartis
Pfizer
AstraZeneca
Pfizer
Pfizer
Pfizer
AstraZeneca
Pfizer